VYNE 2025 Q1 Earnings Misses Targets with Net Income Decline

VYNE reported its fiscal 2025 Q1 earnings on May 08th, 2025. Results fell short of expectations, with revenue increasing but net income declining significantly. The company did not adjust its guidance, maintaining its projection that cash resources will support operations into the second half of 2026.

Revenue
The total revenue of VYNE increased by 106.1% to $202,000 in 2025 Q1, up from $98,000 in 2024 Q1.

Earnings/Net Income
VYNE's losses deepened to $0.20 per share in 2025 Q1 from a loss of $0.15 per share in 2024 Q1 (33.3% wider loss). Meanwhile, the company's net loss widened to $-8.61 million in 2025 Q1, representing a 37.8% increase from the $-6.25 million loss recorded in 2024 Q1. The EPS reflects a challenging quarter with deeper losses.

Price Action
The stock price of VYNE has dropped 7.80% during the latest trading day, has edged down 2.99% during the most recent full trading week, and has plummeted 15.58% month-to-date.

Post-Earnings Price Action Review
The strategy of purchasing VYNE shares following a revenue increase and holding for 30 days yielded a 9.16% annual return, with 66.88% of months being positive over the past five years. However, this strategy underperformed the benchmark, which achieved a 13.81% annual return and had 69.38% of months in the positive. The maximum drawdown during this period was 23.55%, with a recovery period of 18 months. While the strategy showed some promise, the returns were less robust than those of the benchmark.

CEO Commentary
“During the first quarter of 2025, we continued to progress our Phase 2b trial evaluating repibresib for the treatment of vitiligo, and we anticipate reporting top-line results from this trial mid-year,” said David Domzalski, President and Chief Executive Officer of VYNE. He emphasized the significant unmet need in vitiligo, where only one FDA-approved therapy exists, and expressed confidence that repibresib has the potential to be a highly differentiated therapy. Domzalski noted the Company's commitment to collaborating with the FDA to resolve the clinical hold on the Phase 1b trial for VYN202 and emphasized ongoing efforts to advance their pipeline.

Guidance
Top-line results from the Phase 2b trial of repibresib gel are expected in mid-2025. VYNE anticipates that its cash, cash equivalents, and marketable securities as of March 31, 2025, totaling $50.3 million, will be sufficient to fund operations into the second half of 2026. The Company expects to provide further updates regarding the clinical hold on the Phase 1b trial of VYN202 as it works closely with the FDA to outline necessary steps for resolution.

Additional News
VYNE Therapeutics recently announced the completion of enrollment in their Phase 2b trial evaluating VYN201 gel for nonsegmental vitiligo, marking a significant milestone for the program. This trial will assess the once-daily VYN201 gel's efficacy, safety, and pharmacokinetics in subjects with vitiligo. The company also received approval for the non-proprietary name "repibresib" for VYN201 from the United States Adopted Names Council. VYNE's continuing efforts to advance its pipeline reflect a commitment to bringing differentiated therapies to market, addressing high unmet needs in chronic inflammatory conditions.